Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Can people apply 'FAST' when it really matters? A qualitative study guided by the common sense self-regulation model.

Morrow A, Miller CB, Dombrowski SU.

BMC Public Health. 2019 May 28;19(1):643. doi: 10.1186/s12889-019-7032-6.

2.

Tired and lack focus? Insomnia increases distractibility.

Miller CB, Robertson DJ, Johnson KA, Lovato N, Bartlett DJ, Grunstein RR, Gordon CJ.

J Health Psychol. 2019 Apr 22:1359105319842927. doi: 10.1177/1359105319842927. [Epub ahead of print]

PMID:
31007074
3.

The efficacy of biofeedback for the treatment of insomnia: a critical review.

Lovato N, Miller CB, Gordon CJ, Grunstein RR, Lack L.

Sleep Med. 2019 Apr;56:192-200. doi: 10.1016/j.sleep.2018.12.011. Epub 2018 Dec 26.

PMID:
30846410
4.

Examining the theory-effectiveness hypothesis: A systematic review of systematic reviews.

Dalgetty R, Miller CB, Dombrowski SU.

Br J Health Psychol. 2019 May;24(2):334-356. doi: 10.1111/bjhp.12356. Epub 2019 Feb 21.

PMID:
30793445
5.

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.

Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, Merli M, Lunin SD, Pettitt AR, Nagy Z, Tournilhac O, Abou-Nassar KE, Crump M, Jacobsen ED, de Vos S, Kelly VM, Shi W, Steelman L, Le N, Weaver DT, Lustgarten S, Wagner-Johnston ND, Zinzani PL.

J Clin Oncol. 2019 Apr 10;37(11):912-922. doi: 10.1200/JCO.18.00915. Epub 2019 Feb 11. Erratum in: J Clin Oncol. 2019 Jun 1;37(16):1448.

PMID:
30742566
6.

Digital medicine needs to work.

Espie CA, Carl JR, Stott R, Henry AL, Miller CB.

Lancet. 2018 Dec 22 -Jan 4 2019;392(10165):2694. doi: 10.1016/S0140-6736(18)32519-4. No abstract available.

PMID:
30587365
7.

Sleep interventions for osteoarthritis and spinal pain: a systematic review and meta-analysis of randomized controlled trials.

Ho KKN, Ferreira PH, Pinheiro MB, Aquino Silva D, Miller CB, Grunstein R, Simic M.

Osteoarthritis Cartilage. 2019 Feb;27(2):196-218. doi: 10.1016/j.joca.2018.09.014. Epub 2018 Oct 18. Review.

PMID:
30342087
8.

The Effect of Reciprocity Priming on Organ Donor Registration Intentions and Behavior.

O'Carroll RE, Quigley J, Miller CB.

Ann Behav Med. 2019 May 3;53(6):592-595. doi: 10.1093/abm/kay060.

PMID:
30107471
9.

Getting to the heart of cardiac autonomic dysfunction in insomnia.

Gordon CJ, Dodds KL, Marshall NS, Miller CB, Taylor CE, Philips CL.

J Sleep Res. 2018 Dec;27(6):e12738. doi: 10.1111/jsr.12738. Epub 2018 Jul 31. No abstract available. Erratum in: J Sleep Res. 2019 Feb;28(1):e12815.

PMID:
30062685
10.

Population Structure and Antimicrobial Resistance of Canine Uropathogenic Escherichia coli.

LeCuyer TE, Byrne BA, Daniels JB, Diaz-Campos DV, Hammac GK, Miller CB, Besser TE, Davis MA.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e00788-18. doi: 10.1128/JCM.00788-18. Print 2018 Sep.

11.

The effect of consecutive transmeridian flights on alertness, sleep-wake cycles and sleepiness: A case study.

Gordon CJ, Comas M, Postnova S, Miller CB, Roy D, J Bartlett D, R Grunstein R.

Chronobiol Int. 2018 Oct;35(11):1471-1480. doi: 10.1080/07420528.2018.1493597. Epub 2018 Jul 11.

PMID:
29993295
12.

Sham sleep feedback delivered via actigraphy biases daytime symptom reports in people with insomnia: Implications for insomnia disorder and wearable devices.

Gavriloff D, Sheaves B, Juss A, Espie CA, Miller CB, Kyle SD.

J Sleep Res. 2018 Dec;27(6):e12726. doi: 10.1111/jsr.12726. Epub 2018 Jul 10.

PMID:
29989248
13.

The Internal Consistency and Validity of the Vaccination Attitudes Examination Scale: A Replication Study.

Wood L, Smith M, Miller CB, O'Carroll RE.

Ann Behav Med. 2019 Jan 1;53(1):109-114. doi: 10.1093/abm/kay043.

PMID:
29924312
14.

Sleep health epidemiology in low and middle-income countries: a systematic review and meta-analysis of the prevalence of poor sleep quality and sleep duration.

Simonelli G, Marshall NS, Grillakis A, Miller CB, Hoyos CM, Glozier N.

Sleep Health. 2018 Jun;4(3):239-250. doi: 10.1016/j.sleh.2018.03.001. Epub 2018 Apr 12.

PMID:
29776618
15.

Acceptability, tolerability, and potential efficacy of cognitive behavioural therapy for Insomnia Disorder subtypes defined by polysomnography: A retrospective cohort study.

Miller CB, Espie CA, Bartlett DJ, Marshall NS, Gordon CJ, Grunstein RR.

Sci Rep. 2018 Apr 27;8(1):6664. doi: 10.1038/s41598-018-25033-3.

16.

Agreement between electronic and paper Epworth Sleepiness Scale responses in obstructive sleep apnoea: secondary analysis of a randomised controlled trial undertaken in a specialised tertiary care clinic.

Chen L, Chapman JL, Yee BJ, Wong KKH, Grunstein RR, Marshall NS, Miller CB.

BMJ Open. 2018 Mar 8;8(3):e019255. doi: 10.1136/bmjopen-2017-019255.

17.

Correction to: Community reporting of ambient air polychlorinated biphenyl concentrations near a Superfund site.

Tomsho KS, Basra K, Rubin SM, Miller CB, Juang R, Broude S, Martinez A, Hornbuckle KC, Heiger-Bernays W, Scammell MK.

Environ Sci Pollut Res Int. 2018 Jun;25(17):16401. doi: 10.1007/s11356-017-0765-9.

PMID:
29188594
18.

Community reporting of ambient air polychlorinated biphenyl concentrations near a Superfund site.

Tomsho KS, Basra K, Rubin SM, Miller CB, Juang R, Broude S, Martinez A, Hornbuckle KC, Heiger-Bernays W, Scammell MK.

Environ Sci Pollut Res Int. 2018 Jun;25(17):16389-16400. doi: 10.1007/s11356-017-0286-6. Epub 2017 Oct 27. Erratum in: Environ Sci Pollut Res Int. 2017 Nov 29;:.

19.

An Objective Short Sleep Insomnia Disorder Subtype Is Associated With Reduced Brain Metabolite Concentrations In Vivo: A Preliminary Magnetic Resonance Spectroscopy Assessment.

Miller CB, Rae CD, Green MA, Yee BJ, Gordon CJ, D'Rozario AL, Kyle SD, Espie CA, Grunstein RR, Bartlett DJ.

Sleep. 2017 Nov 1;40(11). doi: 10.1093/sleep/zsx148.

PMID:
28958033
20.

Lactococcus petauri sp. nov., isolated from an abscess of a sugar glider.

Goodman LB, Lawton MR, Franklin-Guild RJ, Anderson RR, Schaan L, Thachil AJ, Wiedmann M, Miller CB, Alcaine SD, Kovac J.

Int J Syst Evol Microbiol. 2017 Nov;67(11):4397-4404. doi: 10.1099/ijsem.0.002303. Epub 2017 Sep 25.

21.

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.

Miller CB, Komrokji RS, Mesa RA, Sun W, Montgomery M, Verstovsek S.

Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):479-487. doi: 10.1016/j.clml.2017.05.015. Epub 2017 May 12.

22.

Gender differences in obstructive sleep apnoea, insomnia and restless legs syndrome in adults - What do we know? A clinical update.

Theorell-Haglöw J, Miller CB, Bartlett DJ, Yee BJ, Openshaw HD, Grunstein RR.

Sleep Med Rev. 2018 Apr;38:28-38. doi: 10.1016/j.smrv.2017.03.003. Epub 2017 Mar 27. Review.

PMID:
28495359
23.

Time Trends in the Family Physician Management of Insomnia: The Australian Experience (2000-2015).

Miller CB, Valenti L, Harrison CM, Bartlett DJ, Glozier N, Cross NE, Grunstein RR, Britt HC, Marshall NS.

J Clin Sleep Med. 2017 Jun 15;13(6):785-790. doi: 10.5664/jcsm.6616.

24.

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.

Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H; COMFORT-I investigators.

J Hematol Oncol. 2017 Feb 22;10(1):55. doi: 10.1186/s13045-017-0417-z.

25.

Heart rate variability in insomnia patients: A critical review of the literature.

Dodds KL, Miller CB, Kyle SD, Marshall NS, Gordon CJ.

Sleep Med Rev. 2017 Jun;33:88-100. doi: 10.1016/j.smrv.2016.06.004. Epub 2016 Jun 28. Review.

PMID:
28187954
26.

Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib.

Ailawadhi S, Akard LP, Miller CB, Jillella A, DeAngelo DJ, Ericson SG, Lin F, Warsi G, Radich J.

Ther Adv Hematol. 2017 Jan;8(1):3-12. doi: 10.1177/2040620716678118. Epub 2016 Nov 24.

27.

Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.

Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Naim A, Parasuraman S, Boyle J, Mascarenhas JO.

Cancer. 2017 Feb 1;123(3):449-458. doi: 10.1002/cncr.30325. Epub 2016 Sep 30.

28.

Determinants and Trends of Gynecologic Minimally Invasive Surgery in Developing Countries.

Haber KM, Miller CB, Chuang L, Shahabi S.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S92-S93. doi: 10.1016/j.jmig.2015.08.249. Epub 2015 Oct 15. No abstract available.

PMID:
27679380
29.

Clusters of Insomnia Disorder: An Exploratory Cluster Analysis of Objective Sleep Parameters Reveals Differences in Neurocognitive Functioning, Quantitative EEG, and Heart Rate Variability.

Miller CB, Bartlett DJ, Mullins AE, Dodds KL, Gordon CJ, Kyle SD, Kim JW, D'Rozario AL, Lee RS, Comas M, Marshall NS, Yee BJ, Espie CA, Grunstein RR.

Sleep. 2016 Nov 1;39(11):1993-2004.

30.

Urine Protein/Creatinine Ratios during Labor: A Prospective Observational Study.

Tanamai VW, Seagle BL, Yeh JY, Brady B, Miller CB, Sena S, Dodge J, Shahabi S, Samuelson R, Norwitz ER, Luo G.

PLoS One. 2016 Aug 1;11(8):e0160453. doi: 10.1371/journal.pone.0160453. eCollection 2016.

31.

The moral animal: virtue, vice, and human nature.

Paulson S, Berlin HA, Miller CB, Shermer M.

Ann N Y Acad Sci. 2016 Nov;1384(1):39-56. doi: 10.1111/nyas.13067. Epub 2016 Jun 1. Review.

PMID:
27248691
32.

On Shermer on morality.

Miller CB.

Ann N Y Acad Sci. 2016 Nov;1384(1):63-68. doi: 10.1111/nyas.13076. Epub 2016 May 19. Review.

PMID:
27199206
33.

Morality is real, objective, and supernatural.

Miller CB.

Ann N Y Acad Sci. 2016 Nov;1384(1):74-82. doi: 10.1111/nyas.13074. Epub 2016 May 19. Review.

PMID:
27198934
34.

In defense of a supernatural foundation to morality: reply to Shermer.

Miller CB.

Ann N Y Acad Sci. 2016 Nov;1384(1):91-96. doi: 10.1111/nyas.13072. Epub 2016 May 19. Review.

PMID:
27198538
35.

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.

Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ.

Haematologica. 2016 Jul;101(7):821-9. doi: 10.3324/haematol.2016.143644. Epub 2016 Apr 21.

36.

Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.

Cortes JE, Lipton JH, Miller CB, Busque L, Akard LP, Pinilla-Ibarz J, Keir C, Warsi G, Lin FP, Mauro MJ.

Clin Lymphoma Myeloma Leuk. 2016 May;16(5):286-96. doi: 10.1016/j.clml.2016.02.002. Epub 2016 Feb 16.

37.

Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.

Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J, Mascarenhas JO.

BMC Cancer. 2016 Feb 27;16:167. doi: 10.1186/s12885-016-2208-2.

38.

Physiological Markers of Arousal Change with Psychological Treatment for Insomnia: A Preliminary Investigation.

Miller CB, Kyle SD, Gordon CJ, Espie CA, Grunstein RR, Mullins AE, Postnova S, Bartlett DJ.

PLoS One. 2015 Dec 18;10(12):e0145317. doi: 10.1371/journal.pone.0145317. eCollection 2015.

39.

Do psychosocial sleep interventions improve infant sleep or maternal mood in the postnatal period? A systematic review and meta-analysis of randomised controlled trials.

Kempler L, Sharpe L, Miller CB, Bartlett DJ.

Sleep Med Rev. 2016 Oct;29:15-22. doi: 10.1016/j.smrv.2015.08.002. Epub 2015 Aug 20. Review.

PMID:
26555938
40.

Detection and Measurement of Unhealthy, Environment-Derived Aerosol Materials in an Emergency Department.

Choi BY, Kobayashi L, Pathania S, Miller CB, Locke ER, Stearns BC, Hudepohl NJ, Patefield SS, Suner S, Williams KA, Machan JT, Jay GD.

HERD. 2015 Fall;9(1):34-53. doi: 10.1177/1937586715592634. Epub 2015 Jul 10.

PMID:
26163569
41.

Agreement between simple questions about sleep duration and sleep diaries in a large online survey.

Miller CB, Gordon CJ, Toubia L, Bartlett DJ, Grunstein RR, D'Rozario AL, Marshall NS.

Sleep Health. 2015 Jun;1(2):133-137. doi: 10.1016/j.sleh.2015.02.007. Epub 2015 Apr 1.

PMID:
29073377
42.

Towards standardisation and improved understanding of sleep restriction therapy for insomnia disorder: A systematic examination of CBT-I trial content.

Kyle SD, Aquino MR, Miller CB, Henry AL, Crawford MR, Espie CA, Spielman AJ.

Sleep Med Rev. 2015 Oct;23:83-8. doi: 10.1016/j.smrv.2015.02.003. Epub 2015 Feb 18. Review.

PMID:
25771293
43.

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H; COMFORT-I investigators.

Haematologica. 2015 Apr;100(4):479-88. doi: 10.3324/haematol.2014.115840. Epub 2015 Jan 23.

45.

Attribution, cognition and psychopathology in persistent insomnia disorder: outcome and mediation analysis from a randomized placebo-controlled trial of online cognitive behavioural therapy.

Espie CA, Kyle SD, Miller CB, Ong J, Hames P, Fleming L.

Sleep Med. 2014 Aug;15(8):913-7. doi: 10.1016/j.sleep.2014.03.001. Epub 2014 Mar 12.

PMID:
24791643
47.

The evidence base of sleep restriction therapy for treating insomnia disorder.

Miller CB, Espie CA, Epstein DR, Friedman L, Morin CM, Pigeon WR, Spielman AJ, Kyle SD.

Sleep Med Rev. 2014 Oct;18(5):415-24. doi: 10.1016/j.smrv.2014.01.006. Epub 2014 Feb 12. Review.

PMID:
24629826
50.

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM.

Haematologica. 2013 Dec;98(12):1865-71. doi: 10.3324/haematol.2013.092155. Epub 2013 Sep 13.

Supplemental Content

Loading ...
Support Center